Cellebrite DI (CLBT) Price Target Lowered by Lake Street to $22

Lake Street has lowered its target price for Cellebrite DI (CLBT) from $24 to $22, citing adjusted expectations for the company's future market performance. Analysts have consistently maintained positive ratings, but with adjusted price targets over recent months. The average one-year target price for CLBT is $23, with a high estimate of $28 and a low estimate of $18, implying an upside of 49.45% from the current price.

Lake Street has revised its target price for Cellebrite DI (CLBT) from $24 to $22, reflecting adjusted expectations for the company's future market performance. This adjustment comes amidst a backdrop of consistent positive analyst ratings, though with downwardly adjusted price targets over recent months. The average one-year target price for CLBT stands at $23, with estimates ranging from $18 to $28, implying an upside of 49.45% from the current price [1].

Cellebrite DI reported strong financial results for the second quarter of 2025, with revenue of $113.3 million, up 18% year-over-year. The company's net income improved significantly to $19.5 million, supported by lower expenses, resulting in a 17% profit margin. Earnings per share (EPS) increased to $0.081, surpassing analyst expectations by 16% [1]. The company's shares have been performing well, rising by 11% over the past week [1].

Cellebrite's appointment of Thomas E. Hogan as CEO has been well-received. Hogan, who has extensive experience in technology and software, brings a wealth of experience to the role. His appointment follows the retirement of CFO Dana Gerner and the acquisition of Corellium, a leader in Arm-based virtualization software, which is expected to broaden the company's market reach [2].

The company's financial outlook remains positive, with revenue forecasted to grow at an average annual rate of 15% over the next three years, outpacing the 13% growth rate expected for the broader software industry in the U.S. [1]. However, the company has noted that until demand converts to contracted spending, its full-year 2025 ARR and revenue outlook may be modestly adjusted [2].

Despite the positive outlook, investors should be aware of potential risks. For instance, the acquisition of Corellium is still pending regulatory approval and may face delays. Additionally, the company's growth may be impacted by market conditions and competitive pressures [1].

References:
[1] https://finance.yahoo.com/news/cellebrite-di-second-quarter-2025-122224256.html
[2] https://investors.cellebrite.com/news-releases/news-release-details/cellebrite-announces-second-quarter-2025-results